Products

What will AGI do for Acrisorcin?

This classification denotes an antifungal agent with the molecular formula C13H10N2.C12H18O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2U918O4BEV, chemically known as 1,3-benzenediol, 4-hexyl-, compd. with 9-acridinamine (1:1) but generally known as acrisorcin, which bears US NIH Compound Identifier 24144. European Medicines Agency schedules Acrisorcin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05251MIG. The term ACRISORCIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). ACRISORCIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule acrisorcin under HS 29339990 and SITC 51577. As of Q4 2014, ACRISORCIN remains the US FDA Preferred Term for this commodity. Acrisorcin bears US NLM identifiers UMLS ID C0301311 and NCI Concept Code C65215. SMILES: OC1C(CCCCCC)CCC(O)C1.N1C2C(C(N)C3C1CCCC3)CCCC2.

How AGI delivers it

Four ways AGI delivers for Acrisorcin

  • Headless SaaS for Agents

    Give your tools an agent-consumable surface (API / MCP / SDK) so agents can do the work.

    For Acrisorcin, give your tools an agent-consumable surface (API / MCP / SDK) so agents can do the work.

  • Services-as-Software

    Get the professional outcome delivered as software, priced on results, not headcount.

    For Acrisorcin, get the professional outcome delivered as software, priced on results, not headcount.

Value flow

How Acrisorcin connects

measured by

  • Assay Potencymodel
  • Assay Puritymodel
  • Chemical Identitymodel
  • Chemical Puritymodel